HEIDELBERG, Germany & CAMBRIDGE, Mass. & CLERMONT-FERRAND, France–(BUSINESS WIRE)– #CHMP–Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, and Laboratoire…
Author: Business Wire
NextGen Healthcare Introduces AI-Driven Ambient Listening Innovation for Ophthalmologists and Optometrists
REMOTE-FIRST COMPANY/CHICAGO–(BUSINESS WIRE)– #NextGenHealthcare–NextGen Healthcare today announced that its AI-driven ambient listening solution NextGen® Ambient Assist is now available to ophthalmologists and optometrists. NextGen Ambient Assist s…
The Canadian Association of Optometrists (CAO) Raises Awareness About the Myopia Epidemic Among Children and the Importance of Limiting Screen Time
OTTAWA, Ontario–(BUSINESS WIRE)–As October marks Children Vision Month, the Canadian Association of Optometrists (CAO) releases a new national campaign to raise awareness about myopia, and to enlighten parents and caregivers about the crucial signifi…
L'Association canadienne des optométristes (ACO) sensibilise à l'épidémie de myopie chez les enfants et à l'importance de limiter le temps devant un écran
OTTAWA, Ontario–(BUSINESS WIRE)–Octobre étant le mois de la santé visuelle des enfants, l’Association canadienne des optométristes (ACO) lance une nouvelle campagne nationale sur la myopie et pour sensibiliser les parents, tuteurs et tutrices à l’imp…
Bausch + Lomb Launches Opal™ Digital Marketplace in the United States
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Opal, a digital e-commerce marketplace. Designe…
Dopavision Presented Key Data From Its MyopiaX-1 Clinical Trial at the 19th International Myopia Conference
BERLIN–(BUSINESS WIRE)–Dopavision presented the primary 6-month clinical data from its proof-of-concept study of MyopiaX, a transformative approach that aims to control juvenile-onset myopia, on Friday, September 27th, 2024 at the 19th International …
Harrow Announces Nashville Expansion
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Tennessee Governor Bill Lee, Department of Economic and Community Development Commissioner Stuart C. McWhorter, and Mark L. Baum, Chief Executive Officer of Harrow, Inc. (Nasdaq: HROW), announced today that …
OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced t…
Aurion Biotech Launches Vyznova® (neltependocel) in Japan for the Treatment of Bullous Keratopathy of the Cornea
SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced the commercial launch of Vyznova® (generic name: neltependocel) i…
Aurion Biotech lance le Vyznova® (neltependocel) au Japon pour le traitement de la kératopathie bulleuse de la cornée
SEATTLE et CAMBRIDGE (Massachusetts), et TOKYO–(BUSINESS WIRE)–Aurion Biotech, qui a pour mission de restaurer la vue de millions de patients grâce à des thérapies régénératives qui changent la vie, a annoncé aujourd’hui la mise sur le marché du Vyzn…
Aurion Biotech在日本推出用于治疗大疱性角膜病变的Vyznova® (neltependocel)
西雅图、马萨诸塞州剑桥和东京–(BUSINESS WIRE)–(美国商业资讯)– Aurion Biotech的使命是通过改变人生的再生疗法恢复数百万患者的视力，公司今天宣布开始在日本市售用于治疗大疱性角膜病变的Vyznova®（通用名称：neltependocel）。公司相信，这是第一种获批用于治疗角膜内皮疾病的细胞疗法；它已在日本获得监管和报销批准。伴随此次商业发布，日本京都府立医科大学(KPUM)的Shigeru Kinoshita, M.D., Ph.D.教授实施了第一台细胞疗法手术。…
Riassunto: Aurion Biotech lancia Vyznova® (neltependocel) in Giappone per il trattamento della cheratopatia bollosa della cornea
SEATTLE e CAMBRIDGE, Mass. e TOKYO–(BUSINESS WIRE)–Aurion Biotech, la cui missione è ripristinare la vista a milioni di pazienti con terapie rigenerative che cambiano la vita, oggi ha annunciato il lancio commerciale di Vyznova® (nome generico: nelte…
Aurion Biotech lança o Vyznova® (neltependocel) no Japão para o tratamento da ceratopatia bolhosa da córnea
SEATTLE e CAMBRIDGE, Massachusetts e TÓQUIO–(BUSINESS WIRE)–A Aurion Biotech, cuja missão é restaurar a visão de milhões de pacientes com terapias regenerativas que mudam suas vidas, anunciou hoje o lançamento comercial do Vyznova® (nome genérico: ne…
Aurion Biotech bringt Vyznova® (Neltependocel) in Japan zur Behandlung der bullösen Keratopathie der Hornhaut auf den Markt
SEATTLE & CAMBRIDGE, Mass. & TOKIO–(BUSINESS WIRE)–Aurion Biotech, dessen Mission es ist, Millionen von Patienten mit lebensverändernden regenerativen Therapien das Augenlicht wiederzugeben, gab heute die Markteinführung von Vyznova® (generischer Nam…
Aurion Biotech在日本推出用於治療大皰性角膜病變的Vyznova® (neltependocel)
西雅圖、麻薩諸塞州劍橋和東京–(BUSINESS WIRE)–(美國商業資訊)– Aurion Biotech的使命是透過改變人生的再生療法恢復數百萬病患的視力，公司今天宣布開始在日本市售用於治療大皰性角膜病變的Vyznova®（通用名稱：neltependocel）。公司相信，這是第一種獲准用於治療角膜內皮疾病的細胞療法；它已在日本獲得監管和報銷核准。伴隨此次商業發表，日本京都府立醫科大學(KPUM)的Shigeru Kinoshita, M.D., Ph.D.教授實施了第一台細胞療法手術。…
Aurion Biotech presenta Vyznova® (neltependocel) en Japón para tratar la queratopatía edematosa de la córnea
SEATTLE Y CAMBRIDGE, Massachusetts Y TOKYO–(BUSINESS WIRE)–Aurion Biotech, cuya misión es devolverles la visión a millones de pacientes con terapias regenerativas que cambian su vida, ha anunciado hoy el lanzamiento comercial de Vyznova® (nombre gené…
Samenvatting: Aurion Biotech lanceert Vyznova® (neltependocel) in Japan voor de behandeling van bulleuze keratopathie van het hoornvlies
SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Aurion Biotech, dat als missie heeft het gezichtsvermogen van miljoenen patiënten te herstellen met levensveranderende regeneratieve therapieën, kondigde vandaag de marktlancering aan van Vyznova® (g…
Aviceda Therapeutics Completes Enrollment of Phase 2b SIGLEC Study Assessing the Safety and Efficacy of AVD-104 for Geographic Atrophy Secondary to AMD
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics, a private, clinical-stage biotech company focused on developing next-generation immunomodulators with a proprietary HALOS™ nanotechnology platform to alleviate chronic, non-resolving inflammation…
GenSight Biologics publie ses résultats financiers du premier semestre 2024 et un point sur ses activités
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les maladie…
GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…